Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects

Eitemau Tebyg

• A large multicentre, randomized, double‐blind, cross‐over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US‐ and EU‐reference biologics
  gan: Bellon, Anne, et al.
  Cyhoeddwyd: (2020)
• Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar Pegfilgrastim
  gan: Desai, Kalpna, et al.
  Cyhoeddwyd: (2016)
• GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes
  gan: von Richter, Oliver, et al.
  Cyhoeddwyd: (2016)
• Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg(®), a pegfilgrastim biosimilar in healthy subjects
  gan: Roth, Karsten, et al.
  Cyhoeddwyd: (2019)
• Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer
  gan: Harbeck, Nadia, et al.
  Cyhoeddwyd: (2016)